Menu Close

Articles on Oxford-AstraZeneca vaccine

Displaying 1 - 20 of 51 articles

At the end of 2020, India applied to the WTO for a temporary suspension of intellectual property rights related to Covid-19. Sanjay Kanojia/AFP

Intellectual property and Covid-19: how can we accelerate vaccination globally?

Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
The AstraZeneca vaccine was 70 per cent effective against symptomatic COVID-19 infection in a large multinational study, and recently reported 76 per cent overall efficacy against symptomatic COVID-19 in another large study done primarily in the United States. THE CANADIAN PRESS/John Woods

AstraZeneca COVID-19 vaccine FAQ: Why do the age recommendations keep changing? Does it cause VIPIT blood clots? Is it effective against variants?

With changing recommendations about AstraZeneca's COVID-19 vaccine making headlines, many people have questions about its use.

Top contributors

More